Probiotics Regulate Intestinal Health and Alleviate Anxiety

Wecare Probiotics Co., Ltd.79 enrolled

Overview

This study is a randomized, double-blind, placebo-controlled trial aimed primarily at investigating the effects of Weizmannia coagulans BC99 on alleviating anxiety and depression and the gut microbiota.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Anxiety Depression

Interventions

probiotics groupDIETARY_SUPPLEMENT

The intervention lasted 8 weeks, with follow-ups at weeks 0 and 12.

Placebo GroupDIETARY_SUPPLEMENT

The intervention lasted 8 weeks, with follow-ups at weeks 0 and 12.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adults aged 18-65 years. 2. Individuals experiencing scientific research, employment-related, or occupational stress, including graduate students or community-dwelling adults with job-related pressure. 3. A Hamilton Depression Rating Scale (HAMD-17) score ≥ 8 and/or a Hamilton 4) Anxiety Rating Scale (HAMA-14) score ≥ 7 at screening. 5)Ability and willingness to voluntarily participate in the study and to provide written informed consent prior to enrollment. Exclusion Criteria: 1. A confirmed previous diagnosis of other psychiatric disorders, including intellectual disability, bipolar disorder, treatment-resistant depression, or suicidal ideation. 2. Pregnant or breastfeeding women. 3. Individuals with known food or drug allergies, or those with alcohol abuse or psychotropic substance abuse. 4. Use of antibiotics or probiotics known to affect gut microbiota for more than one week within one month prior to enrollment. 5. Participants who withdrew from the study, discontinued intervention, or were unable to complete the study for any reason.

Locations (1)

Henan University of Science and Technolog

Luoyang, Henan, China

Outcomes

Primary Outcomes

Assess the changes in the severity of depressive symptoms.

The severity of depressive symptoms is assessed by changes in scores on the Hamilton Depression Rating Scale-17 items (HAMD-17) and the Hamilton Anxiety Rating Scale (HAMA-14). The Hamilton Depression Rating Scale (17-item version) is a clinician-administered rating scale consisting of 17 items. The total score ranges from 0 to 52, with higher scores indicating more severe depressive symptoms. The Hamilton Anxiety Rating Scale (14-item version) is a clinician-administered rating scale consisting of 14 items. The total score ranges from 0 to 56, with higher scores indicating more severe anxiety symptoms.

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.